ZOETIS DRY COW TUBES STAND UP TO THE COMPETITION.

BRAND	**SPECTRAMAST® DC*** *(ceftiofur hydrochloride)* Sterile Suspension	**ALBADRY PLUS®** *(penicillin G procaine and novobiocin sodium)* Suspension	**ToMORROW® Cefa-Dri®** *(cephapirin benzathine)*	**Orbenin®-DC** *(benzathine cloxacillin)*	**Dry-Clox®** *(benzathine cloxacillin)*
ACTIVE INGREDIENT	Ceftiofur 500 mg	Penicillin 200,000 IU and novobiocin 400 mg	Cephapirin 300 mg	Cloxacillin 500 mg	Cloxacillin 500 mg
INDICATIONS	Treatment	Treatment of subclinical mastitis	Treatment of mastitis	Treatment and prophylaxis of mastitis	Treatment of mastitis
LABELED PATHOGENS	*Staph. aureus* *Strep. dysgalactiae* *Strep. uberis*	*Staph. aureus* *Strep. agalactiae*	*Staph. aureus* *Strep. agalactiae*	*Staph. aureus* *Strep. agalactiae*	*Staph. aureus* *Strep. agalactiae*
PRE-SLAUGHTER WITHDRAWAL*	16 days	30 days	42 days	28 days	30 days
MILK DISCARD**	0 hours	72 hours	72 hours	0 hours	0 hours
DRY PERIOD LENGTH	30 days	30 days	30 days	28 days	30 days
AVAILABILITY	R_X	OTC	OTC	R_X	R_X
YEAR INTRODUCED	2005	1983	1978	1975	1975

*After last administration (or treatment)
**Milk discard times begin at first milking post freshening and require completion of a minimum dry cow period.

SPECTRAMAST® DC
(ceftiofur hydrochloride)
Sterile Suspension

KEY FEATURES:

- Attacks more major mastitis-causing pathogens, including *Staphylococcus aureus*, *Streptococcus dysgalactiae* and *Strep. uberis*
- Shortest meat withdrawal — allows you to maximize your management options
- Zero milk discard*** — so you can get them back in the milking string faster
- Greater flexibility in milk and cattle management decisions

Important Safety Information: Inappropriate dosage or treatment intervals with SPECTRAMAST DC and/or failure to complete a minimum dry cow period (30 days) may result in violative milk residues. In cows completing a 30-day dry cow period, no milk discard is necessary. Following treatment with SPECTRAMAST DC, a 16-day pre-slaughter withdrawal is required. As with all drugs, SPECTRAMAST DC should not be used in animals found to be hypersensitive to the product.

ALBADRY PLUS®
(PENICILLIN G PROCAINE AND NOVOBIOCIN SODIUM)
Suspension

KEY FEATURES:

- Unique combination of penicillin and novobiocin provides reliable therapy for subclinical mastitis in dry cows
- Has a synergistic effect on bacterial isolates from bovine intramammary infections[1]
- Bactericidal activity against the two common mastitis-causing pathogens — *Staph. aureus* and *Strep. agalactiae*
- Helps eliminate single-antibiotic failures and reduces the likelihood of resistance

Important Safety Information: Do not use ALBADRY PLUS less than 30 days prior to calving. Milk from treated cows must not be used for food during the first 72 hours after calving. Treated animals must not be slaughtered for food for 30 days following udder infusion. See full Prescribing Information attached.

***Zero milk discard period after calving following a 30-day dry cow period.

[1]Wheeler SJ, Edmondson PW, et al. Effect of Penicillin/Novobiocin (TETRADELTA™ Dry Cow, ALBADRY PLUS® Sterile Suspension) Dry Cow Therapy on Somatic Cell Count of Dairy Cows Over the Dry Period. Proc International Buiatrics Congress 2000.

SPECTRAMAST® DC

brand of ceftiofur hydrochloride sterile suspension

For **Intramammary** Infusion in Dry Dairy Cattle Only

FOR USE IN ANIMALS ONLY — NOT FOR HUMAN USE

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: Ceftiofur hydrochloride is a cephalosporin antibiotic.

Chemical Structure of Ceftiofur Hydrochloride



• HCl

U-64279A

Chemical Name of Ceftiofur Hydrochloride
5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[2-(2-amno-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-3-[[(2-furanylcarbonyl) thio]methyl]-8-oxo, hydrochloride.

Ceftiofur Hydrochloride Sterile Suspension is an oil-based sterile suspension.

Each 10 mL PLASTET® Disposable Syringe Contains:

Ceftiofur Equivalents (as the hydrochloride salt)	500 mg
Microcrystalline Wax	700 mg
Labrafil M 1944 CS	500 mg
Cottonseed Oil	q.s.

INDICATIONS FOR USE

SPECTRAMAST® DC Ceftiofur Hydrochloride Sterile Suspension is indicated for the treatment of subclinical mastitis in dairy cattle at the time of dry off associated with *Staphylococcus aureus, Streptococcus dysgalactiae,* and *Streptococcus uberis*. **SPECTRAMAST® DC** Ceftiofur Hydrochloride Sterile Suspension has been proven effective against *Staphylococcus aureus, Streptococcus dysgalactiae,* and *Streptococcus uberis.*

DOSAGE

Infuse one (1) syringe into each affected quarter at the time of dry off.

DIRECTIONS FOR USING PLASTET® DISPOSABLE SYRINGE

The syringe is designed to provide the choice of either insertion of the full cannula as has traditionally been practiced, or insertion of no more than 1/8 inch of the cannula, as reported by Eberhart, R.J., et. al. 1987. Current Concepts of Bovine Mastitis, 3rd Edition, National Mastitis Council, Arlington, VA.

a. Full insertion: Remove the red end cap by pulling straight up as shown. Gently insert the full cannula into the teat canal; carefully infuse the product.

b. Partial insertion: Remove the red end cap by pulling straight up as shown. Gently insert the exposed white tip into the teat canal; carefully infuse the product.



ADMINISTRATION

Treatment: Wash teats thoroughly with warm water containing a suitable dairy antiseptic. Dry teats thoroughly. Milk out udder completely. Using an alcohol pad provided, wipe off the end of the affected teat using a separate pad for each teat. Choose the desired insertion length (full or partial) and insert tip into teat canal; push plunger to dispense entire contents, massage the quarter to distribute the suspension into the milk cistern.

Reinfection: After successful treatment, reinfection may occur unless good herd management, sanitation, and mechanical safety measures are practiced. Affected cows should be watched carefully to detect recurrence of infection and possible spread to other animals.

CONTRAINDICATIONS

As with all drugs, the use of **SPECTRAMAST® DC** Sterile Suspension is contraindicated in animals previously found to be hypersensitive to the drug.

WARNINGS

Discard Empty Container: DO NOT REUSE
KEEP OUT OF REACH OF CHILDREN

Penicillins and cephalosporins can cause allergic reactions in sensitized individuals. Topical exposures to such antimicrobials, including ceftiofur, may elicit mild to severe allergic reactions in some individuals. Repeated or prolonged exposure may lead to sensitization. Avoid direct contact of the product with the skin, eyes, mouth and clothing. Sensitization of the skin may be avoided by wearing latex gloves.Persons with a known hypersensitivity to penicillin or cephalosporins should avoid exposure to this product.

In case of accidental eye exposure, flush with water for 15 minutes. In case of accidental skin exposure, wash with soap and water. Remove contaminated clothing. If allergic reaction occurs (e.g., skin rash, hives, difficult breathing), seek medical attention.

The material safety data sheet contains more detailed occupational safety information. To report adverse effects in users, to obtain more information or to obtain a material safety data sheet, call 1-800-366-5288.

RESIDUE WARNINGS

1. Milk taken from cows completing a 30-day dry cow period may be used for food with no milk discard due to ceftiofur residues.
2. Following label use, no pre-slaughter withdrawal period is required for neonatal calves born from treated cows regardless of colostrum consumption.
3. Following intramammary infusion, a 16-day pre-slaughter withdrawal period is required for treated cows.
4. Use of this product in a manner other than indicated under DOSAGE might result in violative residues.

CLINICAL MICROBIOLOGY

Ceftiofur is a broad-spectrum cephalosporin antibiotic that exerts its effect by inhibiting bacterial cell wall synthesis. Like other ß-lactam antimicrobial agents, the cephalosporins inhibit cell wall synthesis by interfering with the enzymes essential for peptidoglycan synthesis. This effect results in lysis of the bacterial cell and accounts for the bactericidal nature of these agents. Ceftiofur has demonstrated *in vitro* activity against clinical isolates and isolates from diagnostic laboratories. The results of susceptibility testing of these isolates against ceftiofur are presented in Tables 1 and 2. Appropriate reference strains were also susceptibility tested and their minimum inhibitory concentration (MIC) values and zone of inhibition with a 30 µg disk are presented in Table 4.

Table 1. Ceftiofur MIC values for isolates from a multi-site clinical field study evaluating subclinical mastitis in dry dairy cows in the U.S. during 2000

Organism	No.	MIC_{90}* (µg/mL)	MIC range (µg/mL)
Staphylococcus aureus	300	1.0	≤0.06 to 2.0
Streptococcus dysgalactiae	55	≤0.06	≤0.06 to >64.0
Streptococcus uberis	58	1.0	≤0.06 to 4.0

* The MIC for 90% of the isolates.

Table 2. Ceftiofur MIC values* for mastitis pathogens from diagnostic laboratories in the U.S. and Canada

Organism	No.	Date isolated	MIC_{90}** (µg/mL)	MIC range (µg/mL)
Staphylococcus aureus	135	1991–1992	1.0	0.13 to 2.0
	10	1993	1.0	0.25 to 1.0
	107	1995	1.0	0.25 to 2.0
	61	2000	1.0	≤0.06 to 2.0
Coagulase (-) staphylococci	139	2000–2001	1.0	≤0.06 to 2.0
	15	1991–1992	1.0	≤0.06 to 2.0
Streptococcus dysgalactiae	15	1993	≤0.0039	No range†
	152	1997–1999	0.25	0.25 to 4.0
	64	2000	≤0.06	≤0.06 to 0.5
Streptococcus uberis	22	1991–1992	0.5	≤0.06 to 4.0
	15	1993	0.03	≤0.0039 to 0.06
	133	1997–1999	0.5	0.5 to 8.0
	20	2000	1.0	<0.06 to 2.0
Escherichia coli	39	1991–1992	1.0	0.25 to 1.0
	40	1993	0.5	0.13 to 1.0
	52	2000	0.5	≤0.06 to 1.0

* The above *in vitro* data are available, but their clinical significance is unknown.
** The MIC for 90% of the isolates.
† No range, all isolates yielded the same value.

Based on pharmacokinetic, milk residue and clinical effectiveness studies in dairy cattle following intramammary infusion of ceftiofur and the MIC and disk (30 µg) diffusion data from mastitis pathogens, the following breakpoints are recommended by the Clinical and Laboratories Standards Institute (CLSI) (Table 3).

Table 3. Current recommended interpretive criteria established by CLSI for ceftiofur for Bovine Mastitis

Bovine Mastitis Organisms	Disk Content	Zone diameter (mm)			MIC breakpoint (µg/mL)		
		S	I	R	S	I	R
Staphylococcus aureus *Streptococcus dysgalactiae* *Streptococcus uberis* *Streptococcus agalactiae* *Escherichia coli*	30 µg	≥21	18–20	≤17	≤ 2.0	4.0	≥8.0

S – Susceptible I – Intermediate R – Resistant

Standardized procedures require the use of laboratory control organisms for both standardized diffusion techniques and standardized dilution techniques. The 30 µg ceftiofur sodium disk should give the following zone diameters and the ceftiofur sodium standard reference powder (or disk) should provide the following MIC values for the reference strain. The ceftiofur sodium disks or standard reference powder is appropriate for ceftiofur hydrochloride (Table 4).

Table 4. Acceptable quality control ranges for ceftiofur against CLSI recommended American Type Culture Collection (ATCC) reference strains

Organism (ATCC No.)	Zone diameter* (mm)	MIC range (µg/mL)
Escherichia coli (25922)	26 to 31	0.25 to 1.0
Staphylococcus aureus (29213)	—	0.25 to 1.0
Staphylococcus aureus (25923)	27 to 31	—
Pseudomonas aeruginosa (27853)	14 to 18	16.0 to 64.0

*All testing performed using a 30 µg disk.

EFFECTIVENESS

The effectiveness of a single intramammary (IMM) infusion of ceftiofur hydrochloride for the treatment of subclinical mastitis present at the time of dry off was demonstrated in a randomized block design study. Nineteen veterinary investigators enrolled cows in 21 herds and from these 21 herds, 431 cows and 1708 quarters met enrollment criteria in the study and calved within a 45 to 60 day period following enrollment. The enrollment criteria were whole udder somatic cell counts greater than 400,000 cells/mL or a linear somatic cell count score greater than or equal to 5. Milk microbiologic samples were obtained prior to treatment and at Days 3 and 5 post-calving. There were 5 treatment groups including a negative control group. There were 43 cows in the negative control group and 51 cows in the 500 mg ceftiofur group that had a positive pre-treatment milk culture that were evaluated for treatment success. The primary decision variable was the microbiologic (therapeutic) cure in which bacteria isolated pre-treatment were absent from both post-treatment samples.

In another study in eleven study herds, 446 cows with a somatic cell count (SCC) greater than or equal to 400,000 cells/mL or a linear score greater than or equal to 5 were enrolled. Cows with a dry period of at least 45 days were blocked by lactation (1st + 2nd or ≥3rd). A single quarter milk sample was aseptically obtained from all four quarters for bacterial culture prior to treatment and on Days 3 and 5 post-calving. There were 4 treatment groups including a negative control. There were 84 cows in the negative control and 73 in the 500 mg ceftiofur group that had a positive pre-treatment milk culture that were evaluated for treatment success. The primary decision variable was the microbiologic (therapeutic) cure in which bacteria isolated pre-treatment were absent from both post-treatment samples.

Ceftiofur was found to be effective against *Staphylococcus aureus, Streptococcus dysgalactiae,* and *Streptococcus uberis,* when compared to negative controls. This intramammary ceftiofur formulation was well tolerated. No adverse formulation related events were noted during the entire study. A large multi-location field dose confirmation study and a pilot study demonstrated that 500 mg of ceftiofur infused once per quarter at the time of dry off was effective for the treatment of subclinical mastitis in dairy cattle at the time of dry off.

ANIMAL SAFETY

An udder irritation study was conducted in 22 healthy lactating dairy cows to assess udder irritation following a single intramammary infusion of a sterile oil-based suspension containing 500 mg of ceftiofur into all four quarters followed by milk-out 12 hours later.Throughout the 10 day post-treatment observation period there was a clinically insignificant rise in SCC to mean levels <200,000 cells/mL from the pre-infusion level of <69,000 cells/mL. No clinical signs of udder irritation (swelling, pain, or redness), changes in rectal temperature, or changes in milk production were noted in this study. Clinical observations were made during a GLP residue depletion study of 36 cows following a single intramammary infusion of a sterile oil-based suspension containing 500 mg of ceftiofur into all four quarters at the end of lactation. No report of udder irritation or adverse reaction was noted in the daily visual observations over the 14 days immediately following treatment. Collectively, these studies demonstrate that the intramammary infusion of an oil-based sterile suspension containing 500 mg of ceftiofur once into all four quarters at the end of lactation is clinically safe and non-irritating to the udder of non-lactating dairy cows.

MILK AND TISSUE RESIDUE DEPLETION

A metabolism study in cattle using radiolabeled ceftiofur provided the data to establish tolerances for ceftiofur-related residues (as desfuroylceftiofur) in tissue and milk. These tolerances of ceftiofur residues are 0.1 ppm in milk, 0.4 ppm in kidney, 2.0 ppm in liver and 1.0 ppm in muscle.

Pivotal residue decline studies were conducted to assess the depletion of ceftiofur-related residues, measured as desfuroylceftiofur using the official analytical method, in tissues of treated cows, in milk from treated cows, and in tissues of calves born to treated cows. In these studies, nonmastitic cows received 500 mg of ceftiofur per quarter into all four quarters once at dry off. The milk residue depletion study demonstrated that milk produced at calving may be used for human consumption with no discard period when the treatment to calving interval is 30 days or more. The tissue depletion study measured residues in the tissues of treated cows and in the tissues of neonatal calves born to treated cows. In neonatal calves born to treated cows, tissue residues were less than the codified tolerances for kidney, liver and muscle. These data support a zero day pre-slaughter withdrawal period for calves born to treated cows when the treatment to calving interval is 30 days or more, regardless of colostrum consumption. The tissue residue depletion data support a 16-day pre-slaughter withdrawal period following intramammary infusion for treated cows.

STORAGE CONDITIONS

Store at controlled room temperature 20° to 25° C (68° to 77° F). Protect from light. Store plastets in carton until used.

HOW SUPPLIED

SPECTRAMAST® DC Sterile Suspension is available in cartons containing 1 unbroken package of 12–10 mL PLASTET® Disposable Syringes with 12 individually wrapped 70% isopropyl alcohol pads and in pails containing 12 unbroken packages of 12-10 mL PLASTET® Disposable Syringes with 144 individually wrapped 70% isopropyl alcohol pads.

NADA# 141-239, Approved by FDA

www.spectramast.com or call 1-800-733-5500

Revised December 2006

819 771 005
691273

Distributed by:
Pfizer Animal Health
Division of Pfizer Inc, NY, NY 10017

TAKE TIME OBSERVE LABEL DIRECTIONS

Made in France.

ALBADRY PLUS® Suspension

NDC 0009-3139-06, **NDC** 0009-3139-02

brand of penicillin G procaine and novobiocin sodium suspension

For the Treatment of Subclinical Mastitis in Dry Cows

For Udder Instillation in Dry Cows Only

FOR USE IN ANIMALS ONLY — NOT FOR HUMAN USE

Restricted Drug — Use Only as Directed (California)

DESCRIPTION

Each 10 mL PLASTET® Disposable Syringe contains:

Novobiocin sodium equiv. to novobiocin	400 mg
Penicillin G procaine	200,000 IU
Chlorobutanol anhydrous (chloral derivative—used as a preservative)	50 mg in a special bland vehicle

Manufactured by a non-sterilizing process.

INDICATIONS FOR USE

ALBADRY PLUS Suspension is indicated for the treatment, in dry cows only, of subclinical mastitis caused by susceptible strains of *Staphylococcus aureus* and *Streptococcus agalactiae*.

WARNINGS

1. Do not use less than 30 days prior to calving.
2. Milk from treated cows must not be used for food during the first 72 hours after calving.
3. Treated animals must not be slaughtered for food for 30 days following udder infusion.

PRECAUTIONS

Administration of this product in any manner other than shown under DOSAGE may result in drug residues.

DOSAGE

Infuse one tube per quarter at start of dry period (but not less than 30 days prior to calving).

Shake Well Before Using

DIRECTIONS FOR USING THE FLEXI-TUBE® SYSTEM

The FLEXI-TUBE is designed to provide the choice of either insertion of the full cannula, as has traditionally been practiced, or insertion of no more than ⅛ inch of the cannula, as recommended by the National Mastitis Council.

a. Full Insertion: Remove the blue end cap by pulling straight up. Gently insert the full cannula into the teat canal; carefully infuse the product.



b. Partial Insertion: Remove *both* the blue end cap and the red cannula by pushing sideways. Gently insert the exposed blue tip into the teat canal; carefully infuse the product.



ADMINISTRATION

At the time of drying off, but not less than 30 days prior to calving, milk the udder dry. Wash the teats and udder thoroughly with warm water containing a suitable dairy antiseptic. Dry the teats and udder thoroughly. Infuse each quarter using the following procedure. Using the alcohol pads provided, scrub each teat end clean using a separate pad for each teat. Warm ALBADRY PLUS Suspension to body temperature and shake thoroughly. Choose the desired insertion length (full or partial) and insert tip into teat canal. Instill entire contents into the quarter. Massage the udder after treatment to distribute the ALBADRY PLUS Suspension throughout the quarters. Using a suitable teat dip, dip all teats following treatment.

Discard Empty Container; DO NOT RE-USE
KEEP OUT OF REACH OF CHILDREN

STORAGE CONDITIONS

Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].

HOW SUPPLIED

ALBADRY PLUS Suspension is available in unbroken packages of 12-10 mL PLASTET Disposable Syringes with 12 individually wrapped 70% isopropyl alcohol pads and unbroken packages of 144-10 mL PLASTET Disposable Syringes with 144 individually wrapped 70% isopropyl alcohol pads.

For a copy of the Material Safety Data Sheet (MSDS) or to report adverse reactions call Pfizer Animal Health at 1-800-366-5288.

NADA #55-098, Approved by FDA

Made in the United Kingdom for

Distributed by:
Pfizer Animal Health
Exton, PA 19341, USA
Div. of Pfizer Inc
New York , NY 10017

By Norbrook Laboratories Limited
Newry, BT35 6JP, Northern Ireland

Revised December 1999

812 404 007